Cytopathology + More | Primary HPV screening, Pap-HPV cotesting: interim guidance and a retrospective study

Create PDF

1. Zhao C, Moriarty AT, Ghofrani M, et al. Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey. Arch Pathol Lab Med. 2015;139:757–761.
2. FDA approves first human papillomavirus test for primary cervical cancer screening [news release]. Silver Spring, Md.: US Food and Drug Administration; April 24, 2014. www.fda.gov/newsevents/newsroom/pressannounce ments/ucm394773.htm. Accessed June 19, 2015.
3. Davey DD, Husain M. ATHENA design, data—and the FDA’s decision. CAP TODAY. 2014;28(8):64–67.
4. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136:189–197.
5. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical screening: interim clinical guidance. Obstet Gynecol. 2015;125:330–337.
6. Blatt AJ, Kennedy R, Luff D, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123:282–288.
7. American Cancer Society. Cancer facts and figures 2014. www.cancer.org/acs/groups/content/@research/documents/document/acspc-041780.pdf.
8. Stoler MH, Austin RM, Zhao C. Cervical cancer screening should be done by primary HPV testing with genotyping and reflex cytology for women over the age of 25 years. J Clin Microbiol. Epub ahead of print May 6, 2015. doi:10.1128/JCM.01087-15.

Dr. Husain is a professor of pathology, Clinical Sciences Department, University of Central Florida College of Medicine, Orlando. Dr. Davey is interim chair, Department of Clinical Sciences, and assistant dean of graduate medical education, University of Central Florida. Both are members of the CAP Cytopathology Committee.